<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315066</url>
  </required_header>
  <id_info>
    <org_study_id>B0601002</org_study_id>
    <secondary_id>2014-004107-75</secondary_id>
    <secondary_id>B0601002</secondary_id>
    <secondary_id>OX40</secondary_id>
    <nct_id>NCT02315066</nct_id>
  </id_info>
  <brief_title>Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in
      combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in
      order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 23, 2015</start_date>
  <completion_date type="Anticipated">December 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) [Dose Escalation]</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>First and second cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety profile [Dose Expansion]</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and any laboratory abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies and neutralization assays</measure>
    <time_frame>0 hr on Day 1 Cycles 1 to 4, 7 and every other cycle</time_frame>
    <description>Number of participants with the presence of anti-PF-04518600 antibodies and neutralization assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response</measure>
    <time_frame>Baseline, every 6 weeks (Part 1) or 8 weeks (Part 2) until disease progression or unacceptable toxicity</time_frame>
    <description>Number of participants with objective response based on assessment of progression free survival (PFS), time to progression (TTP), duration of stable disease (SD), duration of response (DR) according to RECIST version 1.1 and irRECIST and overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound (free) cell surface OX40 in peripheral blood</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 3, then 0hr on cycles 4 and 7</time_frame>
    <description>Levels of free OX40 receptor expressed on T cells in peripheral blood after dosing with PF 04518600 alone or in combination with PF 05082566.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 6, then 0hr on every cycle</time_frame>
    <description>Cmax will be calculated for PF-04518600 and PF-05082566</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUCt)</measure>
    <time_frame>0 hr and scheduled timepoints post dose on Cycles 1 to 6, then 0hr on every cycle</time_frame>
    <description>Area under the plasma concentration versus time curve will be calculated for PF-04518600 and PF-05082566</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-04518600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OX40 agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OX40 (CD134) agonist plus 4-1BB (CD137) agonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined</description>
    <arm_group_label>PF-04518600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously</description>
    <arm_group_label>PF-04518600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600 plus PF-05082566</intervention_name>
    <description>Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.</description>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600 plus PF-05082566</intervention_name>
    <description>Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.</description>
    <arm_group_label>PF-04518600 plus PF-05082566</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC,
             melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy,
             for which no standard therapy is available or who decline standard therapy.

          -  Part A2 only: Patients with histological or cytological diagnosis of
             advanced/metastatic HCC who are treatment na√Øve and have declined standard of care, or
             have had at least 1 prior line of systemic therapy. Prior anti PD L1/PD 1 therapy is
             allowed.

          -  Part B1 only: Patients with histological or cytological diagnosis of NSCLC, HNSCC,
             melanoma, urothelial bladder carcinoma (including renal pelvis, ureters, urinary
             bladder, and urethra), gastric or squamous cell carcinoma of the uterine cervix who
             progressed on or are intolerant to standard therapy, for which no standard therapy is
             available, or who decline standard therapy.

          -  Part B2

        Arm 1 only:

          1. Ocular melanoma patients with advanced/metastatic disease, or

          2. Cutaneous/acral melanoma patients with advanced/metastatic disease who have received
             checkpoint inhibitor (anti PD L1, anti PD 1, or anti CTLA4) based treatment on which
             disease progressed. [Note: Checkpoint inhibitor may have been part of a combination
             therapy, as long as the combination did not contain OX40 or 4 1BB agonist.] Any
             questions on prior treatment may be discussed with the Sponsor.

        Arm 2 only:

          -  Histological or cytological diagnosis of NSCLC with advanced/metastatic disease.
             Patients must have previously received prior anti PD L1 or anti PD 1 mAb on which
             disease progressed. [Note: Previous anti PD L1 or anti PD 1 mAb may have been part of
             a combination therapy, eg, in combination with chemotherapy, as long as the
             combination did not contain OX40 or 4 1BB agonist.]

          -  Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function

        Exclusion Criteria:

          -  Brain metastases requiring steroids

          -  Major surgery, Radiation therapy within 4 weeks of starting study treatment (except:
             palliative radiotherapy to a limited field is allowed after consultation with
             sponsor's medical monitor at any time during study participation, including during
             screening), or systemic anti-cancer therapy within 4 weeks of study treatment start (6
             weeks for mitomycin C or nitrosoureas)

          -  Active and clinically significant bacterial, fungal, or viral infection

          -  History of active autoimmune disorders

          -  History of immune-mediated adverse events requiring immunosuppressive therapy or were
             grade 3 or higher related to prior immune-modulatory therapy

          -  Prior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2)

          -  Prior anthracycline treatment and at risk of cardiac failure (New York Heart
             Association Class 2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC - Norris Healthcare Center (HC3)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC+USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Regan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Imaging Center of Southern California, Inc.</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UConn Health, Pharmacy</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-2205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UConn Health, Neag Comprehensive Cancer Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital (BWH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General/Chelsea HealthCare Center</name>
      <address>
        <city>Chelsea</city>
        <state>Massachusetts</state>
        <zip>02150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General/North Shore Center for Outpatient Care</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General West</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUMC Research Pharmacy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital-Pathology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart Hospital/Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0601002&amp;StudyName=</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>PF-04518600</keyword>
  <keyword>PF-05082566</keyword>
  <keyword>solid tumors</keyword>
  <keyword>tumors</keyword>
  <keyword>neoplasm metastasis</keyword>
  <keyword>Phase 1</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>liver cancer</keyword>
  <keyword>ocular melanoma</keyword>
  <keyword>melanoma</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>RCC</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <keyword>HNSCC</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>cancer of the cervix</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>lung cancer</keyword>
  <keyword>urothelial bladder carcinoma</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>OX40</keyword>
  <keyword>4-1BB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

